Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Kimberly K. Adkison"'
Autor:
Rashmi Mehta, Chakradhar V. Lagishetty, Konstantinos Angelis, Alicia Aylott, Lesley Kahl, Libby Blair, Jessica Matthews, Brian Wynne, Herta Crauwels, Mark Underwood, Kimberly K. Adkison
Publikováno v:
British Journal of Clinical Pharmacology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a43825031a6846356345b6eef8c88558
https://doi.org/10.1111/bcp.15683
https://doi.org/10.1111/bcp.15683
Autor:
Rajendra P. Singh, Kimberly K. Adkison, Mark Baker, Ridhi Parasrampuria, Allen Wolstenholme, Mark Davies, Nicola Sewell, Cindy Brothers, Ann M. Buchanan
Publikováno v:
Pediatric Infectious Disease Journal. 41:230-237
BACKGROUND The World Health Organization (WHO) 2019 antiretroviral treatment guidelines recommend use of optimal treatment regimens in all populations. Dolutegravir-based regimens are the preferred first-line and second-line treatment in infants and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d27c626f13f1a4d7fffbb57b61580db0
https://doi.org/10.1097/inf.0000000000003366
https://doi.org/10.1097/inf.0000000000003366
Publikováno v:
Clinical Pharmacology in Drug Development
Pharmacokinetics, safety, and tolerability of abacavir 600 mg/dolutegravir 50 mg/lamivudine 300 mg were assessed in this phase 1, single‐arm, open‐label, single‐dose study in fasted healthy male (n = 4) and female (n = 8) participants of Japane
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dbd0b3d9bc18c93fa942fd1b739bba0
https://doi.org/10.1002/cpdd.996
https://doi.org/10.1002/cpdd.996
Autor:
Allen Wolstenholme, Joseph A. Piscitelli, Herta Crauwels, Rashmi Mehta, Kimberly K. Adkison, Caifeng Fu, Brian Wynne
Publikováno v:
Clinical Pharmacology: Advances and Applications. 12:49-52
Dolutegravir 50 mg (DTG) and rilpivirine 25 mg (RPV) are a newly approved 2-drug regimen for the treatment of HIV in virally suppressed patients. A 2-part study evaluated the relative bioavailability and food effect of five experimental fixed-dose co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::442b5f65cc83dfa361a1d5fe6bdb9955
https://doi.org/10.2147/cpaa.s250751
https://doi.org/10.2147/cpaa.s250751
Autor:
Kati Vandermeulen, David Baker, Johannes R. Bogner, Mark R. Underwood, Jessica E. Matthews, Brian Wynne, David Parks, Konstantinos Angelis, Kimberly Y. Smith, Kimberly K. Adkison, Elizabeth A. Blair, Michael Aboud, Marie-Aude Khuong-Josses, Lesley P Kahl, Daniel Podzamczer, Martin Gartland, Chloe Orkin
Publikováno v:
The Lancet HIV. 6:e576-e587
Summary Background Primary analyses of the SWORD-1 and SWORD-2 trials at 48 weeks showed that switching to a two-drug regimen of dolutegravir plus rilpivirine was non-inferior to continuing a standard three-drug or four-drug antiretroviral regimen fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae4be9cc30cd94a140c535d749689c7b
https://doi.org/10.1016/s2352-3018(19)30149-3
https://doi.org/10.1016/s2352-3018(19)30149-3
Autor:
Zhiping Zhang, Amy Eld, Teodora Perger, Kimberly K. Adkison, Harald Vangerow, Mark S. Shaefer, Allen Wolstenholme, Yu Lou, Cynthia McCoig, Katy Hayward
Publikováno v:
Clinical Pharmacology and Therapeutics
In children aged ≤4 years, the relative bioavailability of lamivudine oral solution was 37% lower than that of a tablet formulation. An open‐label, four‐way crossover study was conducted in healthy adults to evaluate the effect of sorbitol, a c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c674ba678d4c725a9c5d6bf1fc9e95aa
https://doi.org/10.1002/cpt.943
https://doi.org/10.1002/cpt.943
Autor:
Naomi Givens, Kimberly K. Adkison, Caifeng Fu, Herta Crauwels, Kristin Di Lullo, Rashmi Mehta, Simon Vanveggel, Shashidhar Joshi, Allen Wolstenholme, Brian Wynne
Publikováno v:
Antimicrobial Agents and Chemotherapy. 62
A complete 2-drug regimen of dolutegravir at 50 mg and rilpivirine at 25 mg was approved to treat HIV-1 infection in virologically suppressed patients after demonstrating acceptable efficacy and tolerability. This study investigated the bioequivalenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::197ac7a3ea5eac3b81cb26ce17e1855d
https://doi.org/10.1128/aac.00748-18
https://doi.org/10.1128/aac.00748-18
Autor:
Jianjun Gan, Lou Yu, David A. Wilfret, Brad Shotwell, Jill Walker, Kimberly K. Adkison, Christian Voitenleitner, Daniel J. Lee, J. Kim, Sharon Baptiste-Brown, Mark Lovern, Amanda Mathis, Andrew Spaltenstein, Lee Moss
Publikováno v:
Clinical Pharmacology in Drug Development. 3:439-448
This first-time-in-human, randomized, double-blind, placebo-controlled, dose-escalation study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of GSK2485852, a hepatitis C virus (HCV) NS5B inhibitor, in 27 chronically infec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::775517143d993389d84d134468e6b1a8
https://doi.org/10.1002/cpdd.142
https://doi.org/10.1002/cpdd.142
Autor:
Oscar Della Pasqua, Evelyne Jacqz-Aigrain, Kimberly K. Adkison, Meindert Danhof, David M. Burger, Chiara Piana, Wei Zhao
Publikováno v:
British Journal of Clinical Pharmacology. 77:861-872
Aim Lamivudine is used as first line therapy in HIV-infected children. Yet, like many other paediatric drugs, its dose rationale has been based on limited clinical data, without thorough understanding of the effects of growth on drug disposition. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3631de4d31432ded5cbcdbcb0b0b226
https://doi.org/10.1111/bcp.12247
https://doi.org/10.1111/bcp.12247
Autor:
David M. Burger, Kimberly K. Adkison, Wei Zhao, Chiara Piana, Oscar Della Pasqua, Meindert Danhof, Evelyne Jacqz-Aigrain
Publikováno v:
British Journal of Clinical Pharmacology. 77:852-860
Aim Little attention has been paid to the effects of compliance and prescription practice on treatment outcome in HIV-infected children. In this context, an evaluation of the role of covariates on pharmacokinetics is required to establish the impact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39e613b40d29e70af2800135fcdb1425
https://doi.org/10.1111/bcp.12246
https://doi.org/10.1111/bcp.12246